{Reference Type}: Systematic Review
{Title}: Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.
{Author}: Nakai K;Kono K;Yamada S;Taniguchi M;Hamano T;Fukagawa M;
{Journal}: Ther Apher Dial
{Volume}: 28
{Issue}: 4
{Year}: 2024 Aug 18
{Factor}: 2.195
{DOI}: 10.1111/1744-9987.14125
{Abstract}: <B>BACKGROUND: </B>Several calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the impact of calcimimetics on the management of serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis.<BR><B>METHODS: </B>A systematic literature search through October 2023 and a meta-analysis were conducted on the effects of upacicalcet, etelcalcetide, evocalcet, and cinacalcet on serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis; we searched PubMed, Ovid MEDLINE, and the Cochrane Central Register of Controlled Trials, and 21 studies comprising 6371 patients undergoing dialysis were included.<BR><B>RESULTS: </B>Participants treated with calcimimetics had lower serum calcium and phosphate levels than placebo.<BR><B>CONCLUSIONS: </B>Calcimimetics significantly reduced serum calcium and phosphate levels compared to placebo in patients with secondary hyperparathyroidism undergoing dialysis, independent of therapeutic strategy or concomitant vitamin D treatment.